ClinicalTrials.Veeva

Menu

A Study of Chemotherapy Treatment for Patients With Ovarian Cancer

Lilly logo

Lilly

Status and phase

Completed
Phase 2

Conditions

Primary Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Cancer

Treatments

Drug: LY573636-sodium

Study type

Interventional

Funder types

Industry

Identifiers

NCT00428610
H8K-MC-JZAG (Other Identifier)
10410

Details and patient eligibility

About

The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done before the first dose and then after every other treatment.

Enrollment

103 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
  • At least 18 years old
  • Have received at least one but no more than 2 systemic treatment regimens containing platinum (does not include regimens received before surgery for this cancer)
  • Have platinum-resistant disease

Exclusion criteria

  • Have received more than 2 systemic treatment regimens for platinum-resistant disease
  • Serious pre-existing medical conditions
  • Actively receiving warfarin (Coumadin) for treatment of venous thrombosis or other prothrombotic conditions

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

103 participants in 1 patient group

LY573636
Experimental group
Description:
LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
Treatment:
Drug: LY573636-sodium

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems